Atlas Trials

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors

Clinical trial NCT07330895 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07330895
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
NOT_YET_RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
CD19+ Relapse/Refractory B-ALL
Start date
2025-12-31
Primary completion
2027-12-31
Enrollment
19

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.